Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Research

The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody

Authors: Reyhan Bayrak, Hacer Haltas, Sibel Yenidunya

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background/Objective

Metastatic adenocarcinoma from an unknown primary site is a common clinical problem. Determining the cytokeratin (CK) 7/CK20 pattern of tumors is one of the most helpful procedures for this purpose since the CK7-/CK20+ pattern is typical of colorectal adenocarcinomas. CDX2, a critical nuclear transcription factor for intestinal development, is expressed in intestinal epithelium and adenocarcinomas. In the present study, we compared the sensitivity and specificity of CDX2 expression and the CK7-/CK20+ phenotype in differentiating colorectal adenocarcinomas from pancreatic and gastric adenocarcinomas.

Methods

CK7/CK20 staining pattern and CDX2 expression were evaluated in 118 cases of colorectal, 59 cases of gastric, and 32 cases of pancreatic adenocarcinomas. The sensitivity, specificity, and positive and negative predictive values of the CK7-/CK20+ phenotype and of CDX2 expression were analyzed.

Results

The CK7-/CK20+ immunophenotype was expressed by 75 of 118 (64%) colorectal and 3 of 59 (5%) gastric tumors and was not observed in any pancreatic adenocarcinomas. The CK7+/CK20+ immunophenotype was expressed in 24/118 (20%) of colon, 28/59 (48%) of gastric and 7/32 (22%) of pancreatic adenocarcinomas. The CK7+/CK20- expression pattern was observed in only 2% (2 of 118) of colorectal carcinomas. CDX2 was expressed in 114 of 118 (97%) colorectal, 36 of 59 (61%) gastric, and 5 of 32(16%) pancreatic adenocarcinomas. There was no significant association between CDX2 expression and tumor differentiation in colorectal carcinomas. In gastric carcinomas, CDX2 expression was more common in intestinal type tumors than in diffuse type carcinomas. The CK7-/CK20+ phenotype showed a specificity of 96.7% in predicting colorectal adenocarcinomas, which was superior to that of CDX2 expression. CDX2 expression at both cut-off levels (> 5% and > 50%) had a higher sensitivity (96.6% and 78%) than the CK phenotype.

Conclusions

Both the CK7-/CK20+ phenotype and expression of the antibody CDX2 are highly specific and sensitive markers of colorectal origin. CDX2 expression should be a useful adjunct for the diagnosis of intestinal adenocarcinomas, particularly when better established markers such as CK7 and CK20 yield equivocal results. The CK7-/CK20+ phenotype is superior in its specificity and positive predictive value and might be preferred.

Virtual slides

The virtual slide(s) for this article can be found here:
http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​4851011866354821​
Appendix
Available only for authorised users
Literature
1.
2.
Varadhachary GR, Abbruzzese JL, Lenzi R: Diagnostic strategies for unknown primary cancer. Cancer. 2004, 100: 1776-85. 10.1002/cncr.20202.CrossRefPubMed
3.
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003, 39: 1990-2005. 10.1016/S0959-8049(03)00547-1.CrossRefPubMed
4.
Pecciarini L, Cangi MG, Doglioni C: Identifying the primary sites of metastatic carcinoma: the increasing role of immunohistochemistry. Curr Diag Pathol. 2001, 7: 168-175. 10.1054/cdip.2001.0079.CrossRef
5.
Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007, 131: 1561-1567.PubMed
6.
Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982, 31: 11-24. 10.1016/0092-8674(82)90400-7.CrossRefPubMed
7.
Campbell F, Herrington CS: Application of cytokeratin 7 and 20 immunohistochemistry to diagnostic pathology. Current Diagnostic Pathology. 2001, 113-122. 7
8.
Van Niekerk CC, Jap PH, Ramaekers FC, Van de Molengraft F, Poels LG: Immunohistochemical demonstration of keratin7 in routinely fixed parafin embedded human tissues. J Pathol. 1991, 165: 145-52. 10.1002/path.1711650210.CrossRefPubMed
9.
Ramaekers C, Van Niekerk C, Poels L, Schaafsma E, Huijsmans A, Robben H, Schaart G, Vooijs P: Use of monoclonal antibodies to keratin7 in differential diagnosis of adenocarcinomas. Am J Pathol. 1990, 641-655. 136
10.
Moll R, Lowe A, Laufer J, Franke WW: Cytokeratin 20 in humancarcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992, 140: 427-447.PubMedCentralPubMed
11.
Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM: Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem Mol Morphol. 1995, 3: 99-107.
12.
Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000, 962-972. 13
13.
Tot T: Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer. 2002, 758-763. 38
14.
Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ: Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: Differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998, 29: 491-497. 10.1016/S0046-8177(98)90065-X.CrossRefPubMed
15.
Tot T: Adenocarcinomas metastatic to the liver. The value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999, 85: 171-177. 10.1002/(SICI)1097-0142(19990101)85:1<171::AID-CNCR24>3.0.CO;2-V.CrossRefPubMed
16.
Wauters CC, Smedts F, Gerrits LG, Bosman FT, Ramaekers FC: Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995, 26: 852-855. 10.1016/0046-8177(95)90006-3.CrossRefPubMed
17.
Loy TS, Calauce RD, Keeney GL: Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol. 1996, 9: 1040-1044.PubMed
18.
Loy TS, Calaluce RD: Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas. Am J Clin Pathol. 1994, 102: 764-767.PubMed
19.
Ikeda S, Fujimori M, Shibata S, Okajima M, Ishizaki Y, Kurihara T, Miyata Y, Iseki M, Shimizu Y, Tokumoto N, Ozaki S, Asahara T: Combined immunohistochemistry of beta-catenin, cytokeratin 7 andcytokeratin 20 is useful in discriminating primary lung from metastatic colorectal carcinoma. BMC Cancer. 2006, 6: 31-36. 10.1186/1471-2407-6-31.PubMedCentralCrossRefPubMed
20.
Bayrak R, Yenidünya S, Haltas H: Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract. 2011, 207: 156-60. 10.1016/j.prp.2010.12.005.CrossRefPubMed
21.
Hernandez BY, Frierson HF, Moskaluk CA, Li YJ, Clegg L, Cote TR, McCusker ME, Hankey BF, Edwards BK, Goodman MT: CK20 and CK7 protein expression in colorectal carcinoma: demonstration of the utility of a population-based tissue microarray. Hum Pathol. 2005, 36: 275-281. 10.1016/j.humpath.2005.01.013.CrossRefPubMed
22.
Zhang PJ, Shah M, Spiegel GW, Brooks JJ: Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2003, 11: 306-310.CrossRefPubMed
23.
Park SY, Kim HS, Hong EK, Kim WH: Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum andt heirvalue in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002, 33: 1078-1085. 10.1053/hupa.2002.129422.CrossRefPubMed
24.
Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P: Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but stil differs from that in colorectal carcinomas metastasis. Am J Surg Pathol. 2000, 24: 870-876. 10.1097/00000478-200006000-00014.CrossRefPubMed
25.
Drummond F, Putt W, Fox M, Edwards YH: Cloning and chromosome assignment of the human CDX2 gene. Ann Hum Genet. 1997, 393-400. 61
26.
Walters JR, Howard A, Rumble HE, Prathalingam SR, Shaw-Smith CJ, Legon S: Differences in expression of homeobox transcription factors in proximal and distal human small intestine. Gastroenterology. 1997, 113: 472-477. 10.1053/gast.1997.v113.pm9247466.CrossRefPubMed
27.
Silberg DG, Swain GP, Suh ER, Traber PG: Cdx1 and Cdx2 expression during intestinal development. Gastroenterology. 2000, 119: 961-971. 10.1053/gast.2000.18142.CrossRefPubMed
28.
Werling RW, Yaziji H, Bacchi CE, Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J SurgPathol. 2003, 27: 303-310.CrossRef
29.
Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF: Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003, 16: 913-919. 10.1097/01.MP.0000086073.92773.55.CrossRefPubMed
30.
Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C: CDX2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J SurgPathol. 2003, 141-149. 27
31.
Saad RS, Silverman JF, Khalifa MA, Rowsell C: CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2009, 196-201. 17
32.
Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL: The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004, 17: 1392-9. 10.1038/modpathol.3800205.CrossRefPubMed
33.
De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL: CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med. 2005, 129: 1100-5.PubMed
34.
Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolós C, David L: Expression of intestinal specific transcription factors, CDX1 and CDX2 in intestinal metaplasia and gastric carcinomas. J Pathol. 2003, 36-40. 199
35.
Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM: Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J SurgPathol. 2005, 359-67. 29
36.
Ortiz-Rey JA, Alvarez C, San Miguel P, Iglesias B, Antón I: Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal type adenocarcinoma. Appl Immunohistochem Mol Morphol. 2005, 13: 142-146. 10.1097/01.pai.0000133058.00588.15.CrossRefPubMed
37.
World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of theDigestive System. Edited by: Hamilton SR, Aaltonen LA. 2000, Lyon, France: IARC Press
38.
Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand. 1965, 64: 31-45.PubMed
39.
AJCC Cancer Staging Manual. Edited by: Edge SB, Byrd DR, Carducci MA, Compton CC. 2009, New York, NY: Springer, 7
40.
Alexander J, Krishnamurthy S, Kovacs D, Dayal Y: Cytokeratin profile of extrahepatic pancreaticobiliary epithelia and their carcinomas: diagnostic application. Appl Immunohistochem Mol Morphol. 1997, 5: 216-222. 10.1097/00022744-199712000-00002.CrossRef
41.
Duval JV, Savas L, Banner BF: Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med. 2000, 124: 1196-1200.PubMed
42.
Mallo GV, Rechreche H, Frigerio JM, Rocha D, Zweibaum A, Lacasa M, Jordan BR, Dusetti NJ, Dagorn JC, Iovanna JL: Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Downregulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis. Int J Cancer. 1997, 74: 35-44. 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1.CrossRefPubMed
43.
Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER: Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001, 2239-2248. 159
44.
Park do Y, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, Zukerberg LR, Song GA, Lauwers GY: CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol. 2010, 54-61. 23
45.
Ha Kim G, Am Song G, Youn Park D, Han Lee S, Hyun Lee D, Oh Kim T, Jae Jo H, Heo J, Hwan Kang D, Cho M: CDX2 expression is increased in gastric cancers with less invasiveness and intestinal mucin phenotype. Scand J Gastroenterol. 2006, 880-886. 41
46.
Liu Q, Teh M, Ito K, Shah N, Ito Y, Yeoh KG: CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer. Mod Pathol. 2007, 20: 1286-1297. 10.1038/modpathol.3800968.CrossRefPubMed
47.
Tot T: Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype. Med Sci Monit. 2004, 10: BR139-143.PubMed
Metadata
Title
The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody
Authors
Reyhan Bayrak
Hacer Haltas
Sibel Yenidunya
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-9

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue

Case Report

Pulmonary artery sarcoma with angiosarcoma phenotype mimicking pleomorphic malignant fibrous histiocytoma: a case report

Research

Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma

Case Report

Basaloid carcinoma of the lung associated with central cavitation: a unique surgical case focusing on cytological and immunohistochemical findings

Case Report

CD20-positive NK/T-cell lymphoma with indolent clinical course: report of case and review of literature

Case Report

A case of Arrhythmogenic right ventricular cardiomyopathy without arrhythmias

Case Report

Sudden death as presenting symptom caused by cardiac primary multicentric left ventricle rhabdomyoma, in an 11-month-old baby. An immunohistochemical study